Millions of individuals suffer from chronic diseases, the by far leading cause of mortality worldwide. These debilitating diseases require continuous monitoring to check on its progress, development of complications, and help adjust treatment. As a result, we are seeing a surge in technological advances that promises to help improve health outcomes, while providing healthcare providers with a cost-effective monitoring platform to help make informed decisions.
The New York-based startup Nanowear is determined to disrupt remote medical monitoring, and is developing textile-based nanosensor technology applicable to multiple medical conditions. Their first product, SimplECG, is a remote cardiac monitoring undergarment that continuously collect multi-channel ECG, heart rate and respiratory rate data from the garment. The real-time data captured is transferred wirelessly via Bluetooth to the patient’s smartphone and further to a secure cloud. An accompanying app enables patients to enter real-time symptoms at the push of a button, which can be accessed by a physician for review through a web-based portal.
The burden of chronic diseases is growing rapidly worldwide, and technology play an increasing role in monitoring and managing treatment. It provide physicians with an objective and consistent feedback, facilitating personalized treatment, while increasing access to care for patients in remote areas and reducing the need for clinic and hospital visits. Nanowear and their innovative SimplECG technology represents the next generation of wearables, a potential game-changing disruptor. The technology address the invasiveness of traditional cardiac monitoring, and provides a platform for the future of preventative medicine.
The real-time, continuous data garnered from everyday clothing enable patients to manage their chronic disease without compromising their day-to-day activities. It could improve health outcomes and improve quality of life for millions of people worldwide, while improving efficiency for healthcare providers. And the technology has extensive applications beyond cardiac monitoring. The startup has already prototyped a headband for screening of neurological disorders, including concussions/TBI, epilepsy and sleep apnea, highlighting the huge potential of the technology.
Nanowear has worked in close partnership with the FDA since early 2015 to understand the dynamic of their device, and in December 2016 received FDA Class II 510(k) clearance. The startup announced in September 2014 that they had raised $1.5 million led by Social+Capital and MAS Holdings, with several angels also participating in the round.